MacroGenics
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, MacroGenics sits in the top decile of US sponsors by registered trial count (#467 of 15,742 sponsors by registered trial count).
MacroGenics: 36 sponsored US clinical trials, 4 recruiting.
MacroGenics sponsors 36 registered US clinical trials on ClinicalTrials.gov, 4 of them currently recruiting, and 21 completed. 2 of these trials are in Phase 3-4 (later-stage) and 33 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Colorectal Carcinoma, with 2 trials.
Top-decile sponsor footprint
MacroGenics ranks in the top decile of sponsors by registered trial count (#467 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
21 of 31 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (67.7%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
36 total, page 1 of 1
A Study of Lorigerlimab in Participants With Advanced Solid Tumors
NCT06730347
A Study of MGC028 in Participants With Advanced Solid Tumors
NCT06723236
A Study of MGC026 in Participants With Advanced Solid Tumors
NCT06242470
A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies
NCT05362773
A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer
NCT05848011
A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors
NCT05551117
A Study of MGD020 Alone or Combined With MGD014 in Persons With HIV-1 on Antiretroviral Therapy
NCT05261191
A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors
NCT05293496
Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck Cancer
NCT04634825
Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer
NCT04082364
MGD019 DART® Protein in Unresectable/Metastatic Cancer
NCT03761017
MGC018 With or Without MGA012 in Advanced Solid Tumors
NCT03729596
MGD014 in HIV-Infected Individuals on Suppressive Antiretroviral Therapy
NCT03570918
MGD007 Combined With MGA012 in Relapsed/Refractory Metastatic Colorectal Cancer
NCT03531632
MGD009/MGA012 Combination in Relapsed/Refractory Cancer
NCT03406949
A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms
NCT03219268
Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors
NCT02982941
Combination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gastric or Gastroesophageal Junction Cancer
NCT02689284
Safety Study of MGD009 in B7-H3-expressing Tumors
NCT02628535
Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer
NCT02492711
Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory Cancer
NCT02475213
Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory Cancer
NCT02381314
Phase 1 Study of MGD010 in Healthy Subjects
NCT02376036
Phase 1 Study of MGD007 in Relapsed/Refractory Metastatic Colorectal Carcinoma
NCT02248805
Flotetuzumab in Primary Induction Failure (PIF) or Early Relapse (ER) Acute Myeloid Leukemia (AML)
NCT02152956
Tissue Procurement Substudy for Participants in Study CP-MGA271-01
NCT01918930
Phase 2 Study of the Monoclonal Antibody MGAH22 (Margetuximab) in Patients With Relapsed or Refractory Advanced Breast Cancer
NCT01828021
Safety Study of MGA271 in Refractory Cancer
NCT01391143
Safety Study of MGAH22 in HER2-positive Carcinomas
NCT01148849
Safety Study of the Monoclonal Antibody Teplizumab (MGA031) in Subjects With Moderate or More Severe Psoriasis
NCT00954915
Protege Encore Study- Clinical Trial of Teplizumab (MGA031) in Children and Adults With Recent-Onset Type 1 Diabetes Mellitus
NCT00920582
Protege Extension Trial - Long Term Follow Up Trial for Subjects Who Completed the Protege Study (CP-MGA031-01)
NCT00870818
Monoclonal Antibody RAV12 and Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer
NCT00625586
A Trial to Evaluate the Safety of a Single Intravenous Infusion of MGAWN1 in Healthy Adults
NCT00515385
The Protégé Study - Clinical Trial of MGA031 in Children and Adults With Recent-Onset Type 1 Diabetes Mellitus
NCT00385697
RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma
NCT00101972
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 25 |
| Phase 2 | 8 |
| Phase 3 | 2 |
Therapeutic Areas
What is open in the MacroGenics pipeline
4 recruiting of 36 indexed (11% open); 21 completed (58%).
Phase mix: 2 late (III/IV) vs 33 early (I/II) (early-phase heavy).
Top condition: Colorectal Carcinoma (2 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
MacroGenics: open-pipeline peers nationwide
Peers matched on 36 registered trials and 11% open enrollment, not the therapeutic-area sidebar.
MacroGenics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 36 trials (± recruiting share)
- Acorda Therapeutics · 36 trials · 0% recruiting
- Baystate Medical Center · 36 trials · 17% recruiting
- Eastern Virginia Medical School · 36 trials · 17% recruiting
- Enanta Pharmaceuticals · 36 trials · 3% recruiting
Sponsors near 11% open enrollment (± trial volume)
- ADC Therapeutics S.A. · 11% recruiting · 18 trials
- Adrian Vella · 11% recruiting · 9 trials
- AIDS Malignancy Consortium · 11% recruiting · 45 trials
- Amylyx Pharmaceuticals · 11% recruiting · 9 trials
Related
What to do with this MacroGenics page
36 registered trials is a research-attention snapshot, not an endorsement of MacroGenics or any single study.
- 4 of MacroGenics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Colorectal Carcinoma is the condition MacroGenics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Colorectal Carcinoma trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
MacroGenics pipeline card: 36 registered trials from official public datasets.Report a data error.